Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Quick Stats
May 18, 202645.0
AI Score
HOLD0.59
Volume Ratio
May 11, 2026
Next Earnings
10
+ve Days (30d)
16
-ve Days (30d)
GERN Stock Summary
Last updated May 18, 2026
GERN is currently trading at $1.23, positioned below its 200-day moving average of $1.41, suggesting bearish momentum. The stock has a 52-week range of $1.04 to $2.01.
Technical Analysis: The 50-day moving average stands at $1.56, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 29.247, suggesting the stock is oversold and potentially undervalued.
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.317, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates GERN at 45.0/100 with a HOLD recommendation.
GERN (Geron Corp) Indicators
Last updated May 18, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 29.247 |
| CMF (20) | -0.317 |
| ROC (10) | -21.656 |
| ADX (14) | 12.066 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.076 |
| AROONOSC (14) | -57.143 |
| WILLAMS %R (14) | -100.0 |
| MFI (14) | 31.554 |
GERN Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
GERN Price vs Max Options Open Interest
GERN Max Change In Options Open Interest
GERN Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GERN Daily Out of Money Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GERN Daily In the Money Options - Sort by Max open Interest (near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GERN Most Active Options by Volume(near term)
18th May 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Geron Corp is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
GERN Moving Averages Analysis
GERN (Geron Corp) Simple Moving Averages
Moving Averages are last updated May 18, 2026
| Days | MA |
|---|---|
| 10 | 1.42 |
| 20 | 1.47 |
| 30 | 1.55 |
| 50 | 1.56 |
| 100 | 1.52 |
| 200 | 1.41 |
GERN Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 827.6 million |
| Earnings/Share ($) | -0.11 |
| Net Proft Margin (%) | -0.3432 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.02 |
| EPS Estimate Next Year ($) | 0.07 |
| WallStreet Target Price ($) | 3.4 |
| Most Recent Quarter |